Why to risk, when there is Agovirax®?

One spray - up to 3 hours of virus protection!1
Reduces the amount of viruses in the nasopharyngeal mucosa by up to 92%2

Effective barrier against more than 200 viruses. Clinically proven

Common cold and flu-like illnesses are caused by a large variety of viruses, such as rhinoviruses, coronaviruses, and others. If viruses have penetrated into the nose, they can attach themselves to the mucous membrane and infect mucosal cells where they multiply and spread.

Agovirax® Nasal Spray creates a protective barrier on the nasal and oral mucosa thus preventing binding and entry of the respiratory viruses into the cells. Thereby viruses cannot attach to the mucosal cells and infection is stopped.

Iota-carrageenan forms a protective barrier & prevents viruses from entering your body

Iota carrageenan creates a protective barrier on the nasal and oral mucosa thus preventing binding and entry of the respiratory viruses, including coronaviruses, into the cells.

Completely safe
to use repeatedly

Suitable for
pregnant women
Suitable for
breastfeeding women
Suitable for children from
1 year old
  • AGOVIRAX® has localised effect. Carragelose® Iota-carrageenan is not absorbed by the cells of the mucosa.
    It has no other side effects besides very rare cases of hypersensitivity.
  • AGOVIRAX® can be used for a longer period of time. There is no potential for addiction or risk of overdose.
  • AGOVIRAX® contains no analgesics, no preservatives, no constituents of animal origin nor greenhouse gases.
    It is lactose and gluten-free and can be used by diabetics and vegans.
Learn more

Results of clinical studies


Agovirax® reduces the viral load (number of viruses) in mucus membranes by more than 90%1


Reduces the risk of contracting SARS-CoV-2 by almost 80%4


Agovirax® shortens the duration of the disease on average by 2.1 days5

  • Agovirax® significantly lowers frequency of relapses3
  • Agovirax® reduces the common cold symptoms2
More clinical studies
  • Graf, C. et al., 2018. Development of a nasal spray containing xylometazoline hydrochloride and iota-carrageenan for the symptomatic relief of nasal congestion caused by rhinitis and sinusitis. International journal of general medicine, 11, 275–283. https://doi.org/10.2147/IJGM.S167123
  • Eccles, R., Meier, C., Jawad, M., Weinmüllner, R., Grassauer, A., & Prieschl-Grassauer, E. (2010). Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respiratory research, 11(1), 108. https://doi.org/10.1186/1465-9921-11-108
  • Ludwig M. et al. Efficacy of a Carrageenan nasal spray in patients with common cold: A randomized controlled trial. Respir Res, vol. 14, no. 1, Nov. 2013, doi: 10.1186/1465-9921-14-124
  • Figueroa, J. M., et al. (2021). Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease. International journal of general medicine, 14, 6277–6286. https://doi.org/10.2147/IJGM.S328486
  • Koenighofer M et al. Carrageenan nasal spray in virus confirmed common cold: Individual patient data analysis of two randomized controlled trials. Multidiscip Respir Med, vol. 9, no. 1, 2014, doi: 10.1186/2049-6958-9-57.